BE2016C015I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2016C015I2 BE2016C015I2 BE2016C015C BE2016C015C BE2016C015I2 BE 2016C015 I2 BE2016C015 I2 BE 2016C015I2 BE 2016C015 C BE2016C015 C BE 2016C015C BE 2016C015 C BE2016C015 C BE 2016C015C BE 2016C015 I2 BE2016C015 I2 BE 2016C015I2
- Authority
- BE
- Belgium
- Prior art keywords
- polypeptide chain
- methods
- biologically active
- constant region
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46960003P | 2003-05-06 | 2003-05-06 | |
US48796403P | 2003-07-17 | 2003-07-17 | |
US53920704P | 2004-01-26 | 2004-01-26 | |
PCT/US2004/014064 WO2005001025A2 (fr) | 2003-05-06 | 2004-05-06 | Hybrides monomeres/dimeres chimeriques d'immunoglobuline |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2016C015I2 true BE2016C015I2 (fr) | 2023-08-09 |
Family
ID=33458764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2016C015C BE2016C015I2 (fr) | 2003-05-06 | 2016-04-06 |
Country Status (28)
Country | Link |
---|---|
US (13) | US7404956B2 (fr) |
EP (7) | EP2357196B9 (fr) |
JP (6) | JP5091480B2 (fr) |
CN (3) | CN1852736B (fr) |
AT (1) | ATE446307T1 (fr) |
AU (1) | AU2004252422B2 (fr) |
BE (1) | BE2016C015I2 (fr) |
BR (2) | BRPI0410345A8 (fr) |
CA (1) | CA2522590C (fr) |
CY (4) | CY1114639T1 (fr) |
DE (1) | DE602004023724D1 (fr) |
DK (4) | DK2361932T3 (fr) |
EA (1) | EA012566B1 (fr) |
ES (3) | ES2582947T3 (fr) |
FR (1) | FR16C0011I2 (fr) |
HK (2) | HK1159649A1 (fr) |
HU (4) | HUE030293T2 (fr) |
IL (2) | IL171779A (fr) |
LT (2) | LTC1625209I2 (fr) |
LU (1) | LU92991I2 (fr) |
NL (1) | NL300799I2 (fr) |
NO (5) | NO339539B1 (fr) |
PL (3) | PL2361932T3 (fr) |
PT (3) | PT2357196T (fr) |
SI (4) | SI1625209T1 (fr) |
TW (1) | TWI353991B (fr) |
UA (1) | UA95436C2 (fr) |
WO (2) | WO2004101739A2 (fr) |
Families Citing this family (376)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7737260B2 (en) * | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Protein complex using an immunoglobulin fragment and method for the preparation thereof |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
CA2522345A1 (fr) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
WO2004100882A2 (fr) * | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Inhibition de medicament se liant a la serumalbumine |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
PT1624891E (pt) * | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
WO2005012484A2 (fr) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Conjugues anticorps-toxines |
US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
WO2006010143A2 (fr) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1] |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
ES2566670T3 (es) | 2004-10-29 | 2016-04-14 | Ratiopharm Gmbh | Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF) |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
AU2006203792B2 (en) | 2005-01-10 | 2011-11-03 | Ratiopharm Gmbh | Glycopegylated Granulocyte Colony Stimulating Factor |
US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CA2609613A1 (fr) * | 2005-05-26 | 2006-11-30 | Schering Corporation | Fusion interferon-igg |
US8633300B2 (en) | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
DK1917276T3 (en) | 2005-08-26 | 2018-05-07 | Ares Trading Sa | Process for Preparation of Glycosylated Interferon Beta |
CA2624189A1 (fr) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Variants de fc dotes de proprietes de liaison aux recepteurs fc optimisees |
CA2625998C (fr) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Anticorps anti-cd30 optimises |
US8153598B2 (en) | 2005-10-19 | 2012-04-10 | Intrexon Corporation | PKD ligands and polynucleotides encoding PKD ligands |
ES2618785T3 (es) | 2005-10-31 | 2017-06-22 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para tratar el cáncer basados en receptores FZD humanos |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
AU2006323925B2 (en) | 2005-12-09 | 2012-08-02 | Ares Trading S.A. | Method for purifying FSH or a FSH mutant |
US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
EP1816201A1 (fr) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée |
TW200745163A (en) * | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
SI2004683T1 (sl) | 2006-03-24 | 2016-09-30 | Biogen Hemophilia Inc. | Pc5 kot encim za obdelavo propeptida faktorja ix |
EP2263696A1 (fr) * | 2006-04-11 | 2010-12-22 | CSL Behring GmbH | Procédé permettant une meilleure récuperation in vivo de polypeptides thérapeutiques. |
AU2007253264A1 (en) | 2006-05-24 | 2007-11-29 | Novo Nordisk Health Care Ag | Factor IX analogues having prolonged in vivo half life |
EP1867660A1 (fr) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine |
DK2256135T3 (da) | 2006-06-14 | 2019-06-11 | Csl Behring Gmbh | Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor |
AU2013202566C1 (en) * | 2006-06-14 | 2018-07-12 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
WO2008036449A2 (fr) * | 2006-06-29 | 2008-03-27 | The Regents Of The University Of California | Anticorps chimiques destinés à l'immunothérapie et à l'imagerie |
US20080274958A1 (en) | 2006-07-21 | 2008-11-06 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
WO2008022152A2 (fr) | 2006-08-14 | 2008-02-21 | Xencor, Inc. | Anticorps optimisés ciblant cd19 |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
BRPI0715794A2 (pt) * | 2006-08-17 | 2013-07-23 | Hoffmann La Roche | conjugado de anticorpo contra ccr5 e peptÍdeo antifusogÊnico |
WO2008051326A2 (fr) * | 2006-08-21 | 2008-05-02 | President And Fellows Of Harvard College | Identification de contactines et de cams l1 en tant que ligands pour la protéine précurseur amyloïde |
US20100267932A1 (en) * | 2006-08-28 | 2010-10-21 | Alex Eon-Duval | Process for the purification of fc-fusion proteins |
DK2061803T4 (da) * | 2006-08-28 | 2022-12-05 | Ares Trading Sa | Fremgangsmåde til oprensning af fc-holdige proteiner |
AU2007299843B2 (en) | 2006-09-18 | 2012-03-08 | Xencor, Inc | Optimized antibodies that target HM1.24 |
WO2008057683A2 (fr) | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Méthodes de purification de conjugués de polypeptides |
US7825093B2 (en) * | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
SG176476A1 (en) * | 2006-11-02 | 2011-12-29 | Daniel J Capon | Hybrid immunoglobulins with moving parts |
WO2008077616A1 (fr) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Facteurs de coagulation modifiés présentant une demi-vie in vivo prolongée |
EP2526962B1 (fr) | 2007-02-12 | 2019-08-14 | CSL Behring GmbH | Application thérapeutique d'inhibiteurs de la sérine protéase de type Kazal |
CA2682897C (fr) | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methodes de traitement a l'aide d'un facteur g-csf glycopegyle |
EP2738257A1 (fr) * | 2007-05-22 | 2014-06-04 | Amgen Inc. | Compositions et procédés pour produire des protéines de fusion bioactives |
EP2170919B8 (fr) | 2007-06-12 | 2016-01-20 | ratiopharm GmbH | Procédé amélioré pour la production de sucres de nucléotide |
TWI554520B (zh) * | 2007-07-20 | 2016-10-21 | 諾華健控股公司 | 在活體中具有延長之半生期以及提高之紅血球生成活性的重組人類紅血球生成素(epo)-fc融合蛋白 |
CL2008002092A1 (es) * | 2007-07-20 | 2009-05-29 | Hoffmann La Roche | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. |
WO2009012600A1 (fr) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Protéines de fusion |
MX2010001363A (es) * | 2007-08-09 | 2010-03-09 | Syntonix Pharmaceuticals Inc | Peptidos inmunomoduladores. |
US8383114B2 (en) | 2007-09-27 | 2013-02-26 | Amgen Inc. | Pharmaceutical formulations |
DK2205258T3 (en) * | 2007-09-28 | 2017-08-28 | Janssen Biotech Inc | Method and structural conformations of antibody preparations with increased resistance to proteases |
EP2203474A1 (fr) * | 2007-10-22 | 2010-07-07 | Merck Serono S.A. | Procédé de purification de protéines de fusion avec fc |
US20100256337A1 (en) * | 2007-10-22 | 2010-10-07 | Merck Serono Sa | Method for purifying an fc-containing protein |
ES2400107T3 (es) * | 2007-10-22 | 2013-04-05 | Merck Serono S.A. | IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado |
MX2010004298A (es) | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. |
EP3381445B1 (fr) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
EP4098661A1 (fr) | 2007-12-26 | 2022-12-07 | Xencor, Inc. | Variantes fc avec liaison altérée en fcrn |
KR101863136B1 (ko) * | 2008-01-24 | 2018-05-31 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법 |
ES2500066T3 (es) | 2008-01-25 | 2014-09-30 | Amgen, Inc | Anticuerpos frente a ferroportina y métodos de uso |
EP2626080A3 (fr) | 2008-02-27 | 2014-03-05 | Novo Nordisk A/S | Molécules de facteur VIII conjuguées |
CA2722600C (fr) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anticorps anti-hepcidine et methodes d'utilisation associees |
AU2009260301B2 (en) | 2008-06-17 | 2015-09-03 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
CA2729296A1 (fr) | 2008-06-17 | 2010-01-28 | Richard D. Dimarchi | Agonistes mixtes bases sur gip destines au traitement de troubles metaboliques et de l'obesite |
ES2531464T3 (es) | 2008-06-24 | 2015-03-16 | Csl Behring Gmbh | Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada |
WO2010014909A1 (fr) * | 2008-08-01 | 2010-02-04 | Syntonix Pharmaceuticals, Inc. | Peptides immunomodulateurs |
CN105079805A (zh) | 2008-09-26 | 2015-11-25 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
US20120021484A1 (en) * | 2008-10-22 | 2012-01-26 | Biogen Idec Ma Inc. | Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins |
CN104922669A (zh) | 2008-11-13 | 2015-09-23 | 通用医疗公司 | 用于通过调整bmp-6来调节铁稳态的方法和组合物 |
CA2742817A1 (fr) | 2008-11-20 | 2010-05-27 | Biogen Idec Ma Inc. | Inactivation de virus par l'arginine |
EP2376521B1 (fr) | 2008-12-19 | 2016-04-13 | Indiana University Research and Technology Corporation | Promédicaments insuliniques à base d'amide |
WO2010096394A2 (fr) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation |
CA2756197A1 (fr) * | 2009-03-24 | 2010-09-30 | Bayer Healthcare Llc | Variants du facteur viii et procedes d'utilisation associes |
EP2411038B1 (fr) | 2009-03-27 | 2016-12-28 | Van Andel Research Institute | Peptides de l'hormone parathyroïdienne et peptides de la protéine apparentée à l'hormone parathyroïdienne ainsi que des procédés d'utilisation |
CN102369215B (zh) | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
PT2417156E (pt) * | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
EA201171259A1 (ru) | 2009-04-22 | 2012-05-30 | Мерк Патент Гмбх | Антительные гибридные белки с модифицированными сайтами связывания fcrn |
EP2443146B1 (fr) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Composés de glucagon actifs sur le récepteur gip |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2011028228A1 (fr) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Compositions de facteurs de coagulation vii et procédés de préparation et d'utilisation de celles-ci |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US20120302737A1 (en) | 2009-09-16 | 2012-11-29 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
US9662271B2 (en) | 2009-10-23 | 2017-05-30 | Amgen Inc. | Vial adapter and system |
NZ600278A (en) | 2009-11-13 | 2014-04-30 | Grifols Therapeutics Inc | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
PT2506868T (pt) * | 2009-12-06 | 2018-02-23 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos e hibridos de factor viii-fc, e métodos de utilização dos mesmos |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
ES2575160T3 (es) | 2010-03-15 | 2016-06-24 | The Board Of Trustees Of The University Of Illinois | Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
EP2371857A1 (fr) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Inhibiteurs de facteur XII pour traiter la maladie de poumon interstitiel |
CN102971337B (zh) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
EA024052B1 (ru) | 2010-06-07 | 2016-08-31 | Эмджен Инк. | Устройство для доставки лекарственного средства |
WO2011159895A2 (fr) | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Agonistes de l'insuline à une seule chaîne très actifs au niveau du récepteur à l'insuline |
AU2011270832B2 (en) | 2010-06-24 | 2016-05-12 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
MX2012014576A (es) | 2010-06-24 | 2013-02-21 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
TW201217526A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
MY192639A (en) * | 2010-07-09 | 2022-08-29 | Bioverativ Therapeutics Inc | Factor ix polypeptides and methods of use thereof |
EP3508573A1 (fr) | 2010-07-09 | 2019-07-10 | Bioverativ Therapeutics Inc. | Systèmes de traitement de facteur viii et procédés associés |
CA2807552A1 (fr) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Acides nucleiques modifies et leurs procedes d'utilisation |
BR112013001847A2 (pt) | 2010-08-24 | 2016-05-31 | Hoffmann La Roche | anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
US9029502B2 (en) | 2010-12-20 | 2015-05-12 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
NZ612297A (en) | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
CA2824143C (fr) | 2011-01-14 | 2018-12-18 | Redwood Bioscience, Inc. | Immunoglobulines polypeptidiques a marquage aldehydique et leur methode d'utilisation |
KR101667096B1 (ko) * | 2011-02-10 | 2016-10-18 | 로슈 글리카트 아게 | 돌연변이 인터루킨-2 폴리펩티드 |
KR101572338B1 (ko) | 2011-02-28 | 2015-11-26 | 에프. 호프만-라 로슈 아게 | 1가 항원 결합 단백질 |
WO2012116926A1 (fr) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Protéines de liaison à un antigène |
EP2497489A1 (fr) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Inhibiteur du facteur XII pour le traitement de la pénombre ischémique cérébrale et l'ischémie d'autres organes |
US9352016B2 (en) | 2011-03-09 | 2016-05-31 | Csl Behring Gmbh | Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
CA2831613A1 (fr) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Administration et formulation d'acides nucleiques genetiquement modifies |
US9480624B2 (en) | 2011-03-31 | 2016-11-01 | Amgen Inc. | Vial adapter and system |
JP6038884B2 (ja) | 2011-04-20 | 2016-12-07 | アムゲン・インコーポレーテッド | 自動式注射装置 |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
RU2600067C2 (ru) | 2011-05-06 | 2016-10-20 | Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретари Оф Дзе Депармент Оф Хелс Энд Хьюман Сёрвисез | Рекомбинантный иммунотоксин, нацеленный на мезотелин |
PL2717898T3 (pl) | 2011-06-10 | 2019-06-28 | Bioverativ Therapeutics Inc. | Związki o działaniu prokoagulacyjnym i sposoby ich stosowania |
LT2723367T (lt) | 2011-06-22 | 2017-08-25 | Indiana University Research And Technology Corporation | Bendri gliukagono/glp-1 receptoriaus agonistai |
EP3513804B1 (fr) | 2011-07-08 | 2022-03-23 | Bioverativ Therapeutics Inc. | Polypeptides chimériques et hybrides de facteur viii et leurs procédés d'utilisation |
IL230564B2 (en) | 2011-07-22 | 2023-09-01 | Csl Ltd | Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses. |
US10656167B2 (en) * | 2011-07-25 | 2020-05-19 | Bioverativ Therapeutics Inc. | Assays to monitor bleeding disorders |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG10201602654SA (en) | 2011-10-03 | 2016-05-30 | Moderna Therapeutics Inc | Modified nucleosides,nucleotides,and nucleic acids,and uses thereof |
AR088267A1 (es) | 2011-10-06 | 2014-05-21 | Hanmi Science Co Ltd | Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos |
DK3045189T3 (en) | 2011-10-14 | 2018-06-18 | Amgen Inc | Injector and mounting method |
JP6158090B2 (ja) * | 2011-10-31 | 2017-07-05 | ダニエル・ジェイ・カポン | 非ペプチドヒンジ部含有フレキシブル抗体様分子 |
ES2672880T3 (es) | 2011-11-17 | 2018-06-18 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor de glucocorticoides |
WO2013090648A1 (fr) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Nucléoside, nucléotide, et compositions d'acide nucléique modifiés |
BR112014015156A2 (pt) | 2011-12-20 | 2020-10-27 | Indiana University Research And Technology Corporation | análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira |
EA029560B1 (ru) | 2012-01-12 | 2018-04-30 | Байоджен Эмэй Инк. | Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта |
MX357403B (es) | 2012-01-12 | 2018-07-09 | Bioverativ Therapeutics Inc | Polipeptidos de factor viii quimericos y usos de los mismos. |
EP2623110A1 (fr) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques |
JP6486686B2 (ja) | 2012-02-10 | 2019-03-20 | ジェネンテック, インコーポレイテッド | 単鎖抗体及び他のヘテロ多量体 |
NZ628014A (en) | 2012-02-15 | 2016-09-30 | Biogen Ma Inc | Recombinant factor viii proteins |
CN104487452A (zh) | 2012-02-15 | 2015-04-01 | 阿穆尼克斯运营公司 | 因子viii组合物及其制备和使用方法 |
DK2814502T3 (en) | 2012-02-15 | 2017-12-18 | Csl Behring Gmbh | Von Willebrand Factor variants with improved Factor VIII binding affinity |
JP2015516143A (ja) | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9159537B2 (en) * | 2012-05-03 | 2015-10-13 | University Of Notre Dame Du Lac | Method for analyzing sample components |
JP2015525222A (ja) | 2012-06-08 | 2015-09-03 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | キメラ性凝固因子 |
US10287564B2 (en) | 2012-06-08 | 2019-05-14 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
ES2674946T3 (es) | 2012-06-21 | 2018-07-05 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
CN104582736A (zh) | 2012-06-21 | 2015-04-29 | 印第安纳大学研究及科技有限公司 | Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物 |
CN104583232B (zh) | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
WO2014001325A1 (fr) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Méthode de fabrication de conjugués d'anticorps à région fc comprenant au moins une entité de liaison qui se lie spécifiquement à une cible et leurs utilisations |
RU2639287C2 (ru) | 2012-06-27 | 2017-12-20 | Ф. Хоффманн-Ля Рош Аг | Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения |
WO2014008480A2 (fr) | 2012-07-06 | 2014-01-09 | Biogen Idec Ma Inc. | Lignée cellulaire exprimant des polypeptides de facteur viii à une seule chaîne et ses utilisations |
DK2882450T3 (da) | 2012-07-11 | 2020-02-24 | Bioverativ Therapeutics Inc | Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf |
KR20150036606A (ko) * | 2012-07-13 | 2015-04-07 | 자임워크스 인코포레이티드 | 항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체 |
WO2014018777A2 (fr) | 2012-07-25 | 2014-01-30 | Biogen Idec Ma Inc. | Essai de surveillance de facteur sanguin et utilisations de celui-ci |
SI2880170T1 (sl) | 2012-08-02 | 2016-12-30 | F. Hoffmann-La Roche Ag | Postopek za proizvodnjo topnega FCR kot FC-fuzije z inertno imunoglobulinsko FC-regijo in uporabe le-tega |
TWI810729B (zh) | 2012-09-25 | 2023-08-01 | 美商百歐維拉提夫治療公司 | Fix多肽的應用 |
EP2908847B1 (fr) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Procédés d'utilisation d'une dose fixe d'un facteur de coagulation |
WO2014066328A1 (fr) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Méthodes de traitement de tumeurs neuro-endocrines à l'aide d'agents liants de parcours wnt |
WO2014070953A1 (fr) | 2012-10-30 | 2014-05-08 | Biogen Idec Ma Inc. | Procédés d'utilisation du polypeptide fviii |
EP4234694A3 (fr) | 2012-11-21 | 2023-09-06 | Amgen Inc. | Dispositif d'administration de médicaments |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
HUE063051T2 (hu) | 2013-02-15 | 2023-12-28 | Bioverativ Therapeutics Inc | Optimalizált VIII. faktor gén |
US10286047B2 (en) | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
WO2014139994A1 (fr) | 2013-03-11 | 2014-09-18 | Novo Nordisk Health Care Ag | Composés d'hormone de croissance |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
US10492990B2 (en) | 2013-03-15 | 2019-12-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
US9623088B2 (en) | 2013-03-15 | 2017-04-18 | Bioverativ Therapeutics Inc. | Factor VIII polypeptide formulations |
EP4039281A1 (fr) * | 2013-03-15 | 2022-08-10 | Biomolecular Holdings LLC | Immunoglobuline hybride contenant une liaison non peptidyle |
TWI580451B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法 |
AU2014228938B2 (en) | 2013-03-15 | 2019-05-02 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
NZ631098A (en) | 2013-03-15 | 2016-09-30 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
AU2014238267B2 (en) | 2013-03-22 | 2019-08-15 | Amgen Inc. | Injector and method of assembly |
EP2796145B1 (fr) | 2013-04-22 | 2017-11-01 | CSL Ltd. | Un complexe covalent de facteur von willebrand et de faktor viii conjugé par un pont disulfure |
WO2014207199A1 (fr) | 2013-06-28 | 2014-12-31 | Csl Behring Gmbh | Polythérapie utilisant un inhibiteur du facteur xii et un inhibiteur de c1 |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
EP3875106A1 (fr) | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Purification des molécules fviii chimériques |
EP3033097B1 (fr) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Fusions de factor viii-xten et leurs utilisations. |
CN103599527A (zh) * | 2013-08-16 | 2014-02-26 | 安源生物科技(上海)有限公司 | 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物 |
CN103397009B (zh) * | 2013-08-16 | 2015-06-03 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
US9322037B2 (en) * | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CA2922912A1 (fr) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Anticorps a chaine legere variable commune echangee a domaine multispecifique |
MX2016005315A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Sistema de administracion de farmacos con control sensible a la temperatura. |
MX2016005312A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Inyector y metodo de montaje. |
EP3065769A4 (fr) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Composé de fusion procoagulant |
PL3068797T3 (pl) | 2013-11-11 | 2020-06-29 | Wake Forest University Health Sciences | Konstrukty wielowalentnego celowania w nowotwory |
EP3074424A4 (fr) | 2013-11-27 | 2017-06-14 | Zymeworks Inc. | Produits de recombinaison de liaison à l'antigène bispécifiques ciblant her2 |
US10325687B2 (en) | 2013-12-06 | 2019-06-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
CN106029087A (zh) | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
WO2015095809A1 (fr) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Utilisation de cultures de semences sous perfusion pour améliorer la capacité de production en alimentation programmée de produits biopharmaceutiques et la qualité des produits |
CN106456718A (zh) | 2014-01-10 | 2017-02-22 | 比奥根Ma公司 | 因子viii嵌合蛋白及其用途 |
KR102567586B1 (ko) | 2014-02-04 | 2023-08-16 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도 |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
KR102587838B1 (ko) * | 2014-03-14 | 2023-10-12 | 바이오몰레큘러 홀딩스 엘엘씨 | 비-펩티드 결합을 함유하는 하이브리드 면역글로불린 |
HUE041976T2 (hu) * | 2014-04-11 | 2019-06-28 | Medimmune Llc | Cisztein-módosított ellenanyagokat tartalmazó konjugált vegyületek |
WO2015171777A1 (fr) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Auto-injecteur comprenant des éléments de réduction de choc |
JP6817074B2 (ja) | 2014-06-03 | 2021-01-20 | アムジエン・インコーポレーテツド | 制御可能な薬物送達システム及び使用方法 |
BR112016029624A2 (pt) | 2014-06-18 | 2017-10-24 | Csl Behring Gmbh | terapia usando um inibidor do fator xii em um distúrbio neurotraumático |
EP3160478A4 (fr) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Gène du facteur ix optimisé |
BR112016030950A2 (pt) | 2014-07-02 | 2018-03-27 | Csl Ltd | polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira. |
WO2016049036A1 (fr) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Anticorps anti-hepcidine humanisés et utilisations de ceux-ci |
WO2016046301A1 (fr) | 2014-09-26 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'adrénomédulline stabilisés et leur utilisation |
US10695506B2 (en) | 2014-10-14 | 2020-06-30 | Amgen Inc. | Drug injection device with visual and audio indicators |
EA201700181A1 (ru) | 2014-10-14 | 2017-09-29 | Галозим, Инк. | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
CN106999602B (zh) * | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
ES2764111T3 (es) | 2014-12-03 | 2020-06-02 | Hoffmann La Roche | Anticuerpos multiespecíficos |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
ES2898469T3 (es) | 2014-12-19 | 2022-03-07 | Amgen Inc | Dispositivo de administración de medicamentos con sensor de proximidad |
US20180170992A1 (en) | 2015-01-26 | 2018-06-21 | The University Of Chicago | CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 |
EP3250609A4 (fr) | 2015-01-26 | 2018-07-11 | The University of Chicago | Agents de liaison à l'il13ra alpha 2 et leur utilisation dans le traitement du cancer |
WO2016125495A1 (fr) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anticorps comprenant un domaine se liant à l'antigène dépendant de la concentration d'ions, variants de la région fc, anticorps se liant à l'il-8, et leurs utilisations |
JP6484345B2 (ja) | 2015-02-17 | 2019-03-20 | アムジエン・インコーポレーテツド | 固定及び/または戻りが真空によって支援された薬物送達装置 |
US11806509B2 (en) | 2015-02-27 | 2023-11-07 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement |
CA2980757A1 (fr) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Proteines de fusion associees a la follistatine et leurs utilisations |
WO2016188905A1 (fr) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Procédés de préparation du facteur willebrand modifié |
CA2986626A1 (fr) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Polypeptides du facteur von willebrand tronque pour le traitement de l'hemophilie |
EP3303380B1 (fr) | 2015-06-02 | 2020-01-15 | Novo Nordisk A/S | Insulines à extensions recombinées polaires |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
WO2017039786A1 (fr) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Adaptateur d'ensemble de seringue pour une seringue |
MX2018003005A (es) | 2015-09-18 | 2018-04-11 | Chugai Pharmaceutical Co Ltd | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos. |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
WO2017070167A1 (fr) | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Méthodes et compositions pour protéines de fusion du facteur ix |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
CN105384828B (zh) * | 2015-12-18 | 2019-06-21 | 中国科学技术大学 | 长效干扰素-α及其改造方法 |
EP3184149A1 (fr) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Glycoprotéine v soluble pour le traitement de maladies thrombotiques |
RU2647769C2 (ru) * | 2015-12-30 | 2018-03-19 | Закрытое Акционерное Общество "Биокад" | Химерный улучшенный рекомбинантный фактор VIII |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
SG10201912498YA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated truncated von willebrand factor |
AU2017205776B2 (en) | 2016-01-07 | 2020-09-10 | CSL Behring Lengnau AG | Mutated von Willebrand factor |
CN108779176A (zh) * | 2016-01-11 | 2018-11-09 | 印希比股份有限公司 | 多价和多特异性41bb结合融合蛋白 |
SG10201913278PA (en) | 2016-02-01 | 2020-02-27 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
CN106397599B (zh) | 2016-02-23 | 2020-08-07 | 上海交通大学 | 二价双特异性抗体杂交蛋白的表达和制备方法 |
CN106397598B (zh) * | 2016-02-23 | 2020-07-14 | 上海交通大学 | 多价多特异性抗体及免疫杂合蛋白的表达和制备方法 |
EP4035711A1 (fr) | 2016-03-15 | 2022-08-03 | Amgen Inc. | Réduction de la probabilité de rupture de verre dans des dispositifs d'administration de médicament |
AU2017247004B2 (en) | 2016-04-06 | 2022-07-07 | Csl Limited | Method of treating atherosclerosis |
JP2019515904A (ja) * | 2016-04-14 | 2019-06-13 | アイコニック セラピューティクス,インコーポレイテッド | 新血管新生に関連する障害を治療するための組成物および方法 |
JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール.ピー.シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
EP3453758A4 (fr) | 2016-05-02 | 2019-12-04 | Ajinomoto Co., Inc. | Protéine fc contenant un groupe azide |
CA3018426A1 (fr) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Ensemble manchon de flacon |
EP3458988B1 (fr) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée |
JP7084878B2 (ja) | 2016-05-16 | 2022-06-15 | 武田薬品工業株式会社 | 抗第IX因子Padua抗体 |
EP3465124A1 (fr) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Appareils et procédés d'essai au choc destinés aux dispositifs d'administration de médicaments |
WO2018004842A1 (fr) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact |
WO2018034784A1 (fr) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Dispositif d'administration de médicament avec détection de positionnement. |
MX2019003567A (es) | 2016-09-28 | 2019-12-02 | Cohbar Inc | Peptidos terapeuticos relacionados con mots-c. |
WO2018081234A1 (fr) | 2016-10-25 | 2018-05-03 | Amgen Inc. | Injecteur porté sur le corps |
US11249082B2 (en) | 2016-10-29 | 2022-02-15 | University Of Miami | Zika virus assay systems |
WO2018087267A1 (fr) | 2016-11-11 | 2018-05-17 | Csl Behring Recombinant Facility Ag | Polypeptides du facteur de von willebrand tronqué pour le traitement de l'hémophilie |
SG10201912768YA (en) | 2016-11-11 | 2020-02-27 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
CN110520150A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 使用嵌合凝血因子治疗血友病性关节病的方法 |
US20200085915A1 (en) | 2016-12-02 | 2020-03-19 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
EP3573641A4 (fr) * | 2017-01-25 | 2020-11-11 | Iconic Therapeutics, Inc. | Procédés de traitement de troubles associés à l'angiogenèse et à la néovascularisation |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
US11369736B2 (en) | 2017-02-17 | 2022-06-28 | Amgen Inc. | Cannula insertion and retraction mechanisms |
WO2018156892A1 (fr) | 2017-02-23 | 2018-08-30 | Adrx, Inc. | Inhibiteurs peptidiques de l'agrégation du facteur de transcription |
EP3589295A4 (fr) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | Compositions et méthodes de thérapie par lymphocytes t car |
MX2019010544A (es) | 2017-03-06 | 2019-10-21 | Amgen Inc | Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion. |
JP2020509839A (ja) | 2017-03-07 | 2020-04-02 | アムジエン・インコーポレーテツド | 超過圧力による針の挿入 |
JP2020509837A (ja) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | 薬剤送達装置のための挿入機構 |
AU2018235945A1 (en) * | 2017-03-14 | 2019-10-17 | Ohio State Innovation Foundation | Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates |
EP3570871B1 (fr) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Procédé de glyco-ingénierie in vitro d'une protéine de stimulation de l'érythropoïèse |
US11957883B2 (en) | 2017-03-28 | 2024-04-16 | Amgen Inc. | Plunger rod and syringe assembly system and method |
JP2020513019A (ja) | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー/エス | オリゴマー伸長インスリン−Fcコンジュゲート |
MA49131A (fr) * | 2017-04-21 | 2020-03-25 | Hoffmann La Roche | Utilisation d'antagonistes de klk5 pour le traitement d'une maladie |
BR112019023543A2 (pt) * | 2017-05-10 | 2020-05-26 | Albajuna Therapeutics, S.L. | Derivados de proteína de fusão fc com alta atividade dual antiviral e imunomoduladora do hiv |
CA3066077A1 (fr) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Inhibiteur d'agregation de tau |
CA3061982A1 (fr) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Ensemble de seringue d'un appareil d'administration de medicament et procede d'assemblage |
EP3634546A1 (fr) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Dispositif d'administration de médicament entraîné par couple |
JP7195276B2 (ja) | 2017-06-22 | 2022-12-23 | アムジエン・インコーポレーテツド | デバイス起動による衝突/衝撃の低減 |
KR20200018690A (ko) | 2017-06-22 | 2020-02-19 | 체에스엘 베링 렝나우 아게 | 절단된 vwf에 의한 fviii 면역원성의 조절 |
EP3641861A1 (fr) | 2017-06-23 | 2020-04-29 | Amgen Inc. | Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
WO2019018169A1 (fr) | 2017-07-21 | 2019-01-24 | Amgen Inc. | Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage |
US11617837B2 (en) | 2017-07-25 | 2023-04-04 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
SG11202000764RA (en) | 2017-08-09 | 2020-02-27 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
CA3073062A1 (fr) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Inhibiteurs peptidiques d'agregation de tau |
MA49897A (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc | Injecteur sur-corps avec patch adhésif stérile |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
EP3691716B1 (fr) | 2017-10-06 | 2023-11-29 | Amgen Inc. | Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé |
US11464903B2 (en) | 2017-10-09 | 2022-10-11 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
EP3703779A1 (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc. | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
EP3707075A1 (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Ensembles de remplissage-finition et procédés associés |
US20200261648A1 (en) | 2017-11-06 | 2020-08-20 | Amgen Inc. | Drug delivery device with placement and flow sensing |
MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
WO2019099322A1 (fr) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Auto-injecteur avec détection de décrochage et de point d'extrémité |
WO2019099324A1 (fr) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament |
JP7002927B2 (ja) | 2017-11-22 | 2022-01-20 | 本田技研工業株式会社 | 駆動軸配置構造 |
TW201940182A (zh) | 2018-01-22 | 2019-10-16 | 美商安德賽特公司 | Car t 細胞之使用方法 |
EP3746136A1 (fr) | 2018-02-01 | 2020-12-09 | Bioverativ Therapeutics Inc. | Utilisation de vecteurs lentiviraux exprimant le facteur viii |
PE20210313A1 (es) | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso |
CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
KR20210020030A (ko) | 2018-05-18 | 2021-02-23 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US11830582B2 (en) | 2018-06-14 | 2023-11-28 | University Of Miami | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents |
US20210260161A1 (en) | 2018-07-03 | 2021-08-26 | Bristol-Myers Squibb Company | Fgf-21 formulations |
CA3103682A1 (fr) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Dispositifs d'administration pour l'administration de medicaments |
WO2020023336A1 (fr) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
CN112469454B (zh) | 2018-07-24 | 2024-01-26 | 安进公司 | 用于施用药物的输送装置 |
MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
AU2019319984A1 (en) | 2018-08-09 | 2021-03-04 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
JP2022500095A (ja) | 2018-09-24 | 2022-01-04 | アムジエン・インコーポレーテツド | インターベンション投薬システム及び方法 |
EP3856283A1 (fr) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament |
WO2020072577A1 (fr) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Systèmes d'injection pour administration de médicament avec transmission de force interne |
EP3860686A1 (fr) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Dispositif d'administration de médicament ayant un indicateur de dose |
CN109439679A (zh) * | 2018-10-09 | 2019-03-08 | 上海市儿童医院 | 一种高活性重组人凝血因子ix融合蛋白及其制备方法 |
EP3866889A1 (fr) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament |
AU2019361919A1 (en) | 2018-10-15 | 2021-03-18 | Amgen Inc. | Drug delivery device having damping mechanism |
WO2020086408A1 (fr) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bioprocédé d'expression génique transitoire basé sur une perfusion à haut rendement |
EP3873566A1 (fr) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
WO2020092056A1 (fr) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Dispositifs d'administration de médicament à rétraction d'aiguille partielle |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
US20220226484A1 (en) | 2019-01-28 | 2022-07-21 | Cohbar, Inc. | Therapeutic peptides |
CA3131648A1 (fr) | 2019-03-19 | 2020-09-24 | CSL Behring Lengnau AG | Variants du facteur ix et leurs utilisations en therapie |
US20220323519A1 (en) | 2019-04-17 | 2022-10-13 | Codiak Biosciences, Inc. | Compositions of exosomes and aav |
MX2021012557A (es) | 2019-04-24 | 2021-11-12 | Amgen Inc | Conjuntos y metodos de verificacion de esterilizacion de jeringuillas. |
BR112021022940A2 (pt) | 2019-05-17 | 2022-01-18 | Csl Behring Ag | Haptoglobina para uso no tratamento de um resultado neurológico secundário após um acidente vascular cerebral hemorrágico |
CN114174326A (zh) | 2019-06-18 | 2022-03-11 | 拜耳公司 | 长期稳定的肾上腺髓质素类似物及其用途 |
CN114072420A (zh) | 2019-07-04 | 2022-02-18 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
AU2020337250A1 (en) | 2019-08-23 | 2022-03-03 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
US20210113634A1 (en) | 2019-09-30 | 2021-04-22 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
JP2023500953A (ja) | 2019-11-11 | 2023-01-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第viii因子に対する寛容を誘導するためのポリペプチド |
US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
AU2020407233A1 (en) | 2019-12-20 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Novel IL2 agonists and methods of use thereof |
IL293994A (en) | 2019-12-23 | 2022-08-01 | Denali Therapeutics Inc | Variants of progranulin, preparations containing them and their uses |
KR20220139915A (ko) | 2020-02-06 | 2022-10-17 | 브리스톨-마이어스 스큅 컴퍼니 | Il-10 및 그의 용도 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CN116568327A (zh) | 2020-11-20 | 2023-08-08 | 德国杰特贝林生物制品有限公司 | 治疗抗体介导的排斥反应的方法 |
JP2024504822A (ja) | 2021-02-01 | 2024-02-01 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | 出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法 |
WO2022234070A1 (fr) | 2021-05-07 | 2022-11-10 | Csl Behring Ag | Système d'expression pour la production d'une chaîne bêta de l'haptoglobine (hp) recombinante |
WO2022246055A1 (fr) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Procédé d'optimisation d'une recette de remplissage pour un récipient de médicament |
WO2024047219A1 (fr) | 2022-09-02 | 2024-03-07 | Csl Behring Ag | Haptoglobine destinée à être utilisée dans le traitement ou la prévention d'une réponse érectile exagérée ou d'un dysfonctionnement érectile |
Family Cites Families (312)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US660843A (en) * | 1900-05-16 | 1900-10-30 | Rebecca Coyle | Nursing-gown. |
US786376A (en) | 1902-05-15 | 1905-04-04 | Fischer Motor Vehicle Company | Electrogasolene-vehicle. |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
US5189015A (en) * | 1984-05-30 | 1993-02-23 | Alfa-Laval Agri International Ab | Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability |
US5077204A (en) | 1984-06-21 | 1991-12-31 | Chiron Corporation | Yeast endopeptidase for basic amino-acid site cleavage, preparation and use |
US4849407A (en) | 1986-08-13 | 1989-07-18 | Zymogenetics, Inc. | Biologically active mosaic proteins |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
DK525384D0 (da) * | 1984-11-05 | 1984-11-05 | Nordisk Insulinlab | Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat |
US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
ATE72838T1 (de) | 1985-04-12 | 1992-03-15 | Genetics Inst | Neue prokoagulierungsproteine. |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
WO1987004187A1 (fr) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | PROCEDE DE PRODUCTION DE PROTEINES DE TYPE FACTEUR VIII:c |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
IL78444A (en) | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
CA1340456C (fr) | 1986-07-07 | 1999-03-23 | Hubert J.P. Schoemaker | Immunoglobulines chimeriques de rongeur/homme specifiques pour antigenes associes a des tumeurs |
NO873164L (no) | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
CA1339445C (fr) | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Molecules d'immunoglobuline hybride recombinante et methode d'utilisation |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
EP0279582A3 (fr) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Séquences d'ADN pour diriger des protéines vers les glandes mammaires afin d'être sécrétées efficacement |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US6018026A (en) * | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
ZA89430B (en) * | 1988-01-22 | 1989-10-25 | Gen Hospital Corp | Cloned genes encoding ig-cd4 fusion proteins and the use thereof |
US5234830A (en) * | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
JP2643968B2 (ja) | 1988-02-03 | 1997-08-25 | サントリー株式会社 | Kex2エンドプロテアーゼ及びその製造方法 |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
WO1990005183A1 (fr) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Recepteurs d'interleukine-4 |
EP0368684B2 (fr) | 1988-11-11 | 2004-09-29 | Medical Research Council | Clonage de séquences d'immunoglobulines de domaines variables. |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2641468A1 (fr) * | 1989-01-11 | 1990-07-13 | Merieux Inst | Anticorps chimeriques anti-recepteur de l'interleukine-2 humaine, leur preparation et compositions pharmaceutiques les contenant |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
SE8901687D0 (sv) | 1989-05-11 | 1989-05-11 | Alfa Laval Agri Int | Fibronectin binding protein as well as its preparation |
DK0474744T3 (da) | 1989-05-22 | 1994-11-21 | Zymogenetics Inc | PDGF-alfa-receptor |
US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5184344A (en) | 1989-08-21 | 1993-02-02 | Ngk Insulators, Ltd. | Recording head including electrode supporting substrate having thin-walled contact end portion, and substrate-reinforcing layer |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
EP0939121B2 (fr) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | Protéines liant le TNF |
US5935815A (en) | 1989-10-25 | 1999-08-10 | Katholieke Universiteit Leuven | Process for micro biological production of proteins |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9009106D0 (en) | 1990-04-23 | 1990-06-20 | 3I Res Expl Ltd | Processes and intermediates for synthetic antibody derivatives |
CA2040099A1 (fr) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine-kinase-negative trkb |
DK0835939T3 (da) | 1990-06-28 | 2006-03-13 | Sanofi Aventis Deutschland | Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse |
US20030064480A1 (en) | 1990-06-28 | 2003-04-03 | Leander Lauffer | Fusion proteins with immunoglobulin portions, the preparation and use thereof |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
JP4236698B2 (ja) | 1990-11-26 | 2009-03-11 | ジェネティックス インスティチュート,リミテッド ライアビリティ カンパニー | 宿主細胞でのpaceの発現およびその使用法 |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
EP0563214A4 (en) * | 1990-12-04 | 1994-08-17 | Wistar Inst | Bifunctional antibodies and method of preparing same |
US5374617A (en) | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
WO1992018628A1 (fr) | 1991-04-19 | 1992-10-29 | Schering Corporation | Sous-unite du recepteur de l'interleukine-3 humaine |
DK0636173T3 (da) * | 1991-05-31 | 1999-05-31 | Genentech Inc | Behandling af HIV associeret immunthrombocytopenisk purpura |
US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
US5346991A (en) | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
US5348856A (en) | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5116753A (en) * | 1991-07-30 | 1992-05-26 | The Salk Institute For Biological Studies | Maintenance of pancreatic islets |
US5932448A (en) * | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5454933A (en) * | 1991-12-16 | 1995-10-03 | Exxon Research And Engineering Company | Deep desulfurization of distillate fuels |
JP3490437B2 (ja) * | 1992-01-23 | 2004-01-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 単量体および二量体抗体フラグメント融合タンパク質 |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
EP0626012B1 (fr) | 1992-02-11 | 2003-07-09 | Cell Genesys, Inc. | Obtention d'homozygotes par ciblage de genes |
ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
WO1994005328A1 (fr) | 1992-08-28 | 1994-03-17 | The Scripps Research Institute | Inhibitions des metastases tumorales par neutralisation de la fonction de la thromboplastine tissulaire |
GB2270845B (en) | 1992-09-24 | 1996-07-10 | Smiths Ind Med Syst Inc | Suction catheter assemblies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
ATE236987T1 (de) | 1992-11-13 | 2003-04-15 | Idec Pharma Corp | Konsensus-kozak-sequenzen zur säugetier- exprimierung |
US5648446A (en) * | 1993-02-24 | 1997-07-15 | Mitsui Toatsu Chemicals, Inc. | Diguanamines and preparation process, derivatives and use thereof |
AU7050994A (en) | 1993-06-01 | 1994-12-20 | Scripps Research Institute, The | Human mutant tissue factor compositions useful as tissue factor antagonists |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US6518013B1 (en) * | 1993-06-07 | 2003-02-11 | Trimeris, Inc. | Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission |
US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US6017536A (en) | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
US6310180B1 (en) * | 1993-06-21 | 2001-10-30 | Vanderbilt University | Method for synthesis of proteins |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
KR950003279A (ko) | 1993-07-29 | 1995-02-16 | 고사이 아끼오 | 플루오로알칸 카르복사미드 유도체의 제조방법 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5648240A (en) * | 1994-05-24 | 1997-07-15 | Texas A&M University | MHC II analog from Staphylococcus aureus |
HU220347B (hu) | 1994-07-11 | 2001-12-28 | Board Of Regents The University Of Texas System | Készítmény az érrendszer specifikus koagulálásához |
WO1996010585A1 (fr) * | 1994-09-30 | 1996-04-11 | Inex Pharmaceuticals Corp. | Conjugues de proteines glycosylees/liposomes et leurs procedes de preparation |
US5596080A (en) * | 1994-10-03 | 1997-01-21 | E. I. Du Pont De Nemours And Company | Crosslinking processes/agents for zein |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
WO1996022024A1 (fr) * | 1995-01-17 | 1996-07-25 | Brigham And Women's Hospital, Inc. | Transport transepithelial specifique de recepteurs d'immunogenes |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5591573A (en) * | 1995-04-10 | 1997-01-07 | Alpha Therapeutic Corporation | Method and system for testing blood samples |
US5869046A (en) * | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5579277A (en) | 1995-05-01 | 1996-11-26 | Apple Computer, Inc. | System and method for interleaving memory banks |
US6184344B1 (en) * | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
BR9609152A (pt) | 1995-06-07 | 1999-05-04 | Trimeris Inc | Processo para tratamento de infecção por hiv em um individuo inibição da replicação do hiv e composição farmaceutica aceitavel util para o tratamento de infecção por hiv |
US5840529A (en) | 1995-08-02 | 1998-11-24 | Clinical Research Institute Of Montreal | Mammalian pro-hormone convertase |
EP1382679A3 (fr) | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Antagonists du proteine apparentee a facteur de croissance endothelial vasculaire (VRP) |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
US20030026779A1 (en) | 1999-10-15 | 2003-02-06 | Liming Yu | Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
CA2198968C (fr) * | 1996-03-04 | 2010-02-09 | Toyofumi Masuda | Procede de production de derives kex2 secretoires |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
JP2000515735A (ja) | 1996-07-03 | 2000-11-28 | ジェネンテック インコーポレーテッド | 肝細胞成長因子レセプターアゴニスト |
CA2203745A1 (fr) | 1996-07-26 | 1998-01-26 | Robert Day | Enzyme de conversion pro-proteinique |
JP2001506967A (ja) | 1996-08-02 | 2001-05-29 | ブリストル―マイヤーズ・スクイブ・カンパニー | 治療およびインビボ診断における免疫グロブリンの使用の結果としての免疫グロブリン誘発毒性の抑制方法 |
US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
WO1998023289A1 (fr) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | Modulation de la fixation de l'igg au fcrn |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
WO1998028424A2 (fr) | 1996-12-23 | 1998-07-02 | Immunex Corporation | Activateur du recepteur de nf-kappab, recepteur membre de la superfamille des recepteurs de tnf |
WO1998031394A2 (fr) | 1997-01-22 | 1998-07-23 | Board Of Regents, The University Of Texas System | Methodes et compositions de thromboplastine tissulaire pour le traitement de la coagulation et des tumeurs |
TW502011B (en) * | 1997-02-05 | 2002-09-11 | Ajinomoto Kk | Process for producing n-long-chain acyl acidic amino acids or salts thereof |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
PT981637E (pt) | 1997-03-14 | 2005-09-30 | Biogen Idec Inc | Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo |
US6673901B2 (en) | 1997-06-12 | 2004-01-06 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6326468B1 (en) | 1997-06-13 | 2001-12-04 | Gryphon Sciences | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution |
EP0885571B1 (fr) * | 1997-06-21 | 2003-08-27 | Tesa AG | Ruban adhésif composite et son utilisation |
US6310183B1 (en) | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
JP4271850B2 (ja) | 1998-01-23 | 2009-06-03 | イミュネックス・コーポレーション | Il−18受容体 |
CZ20003099A3 (cs) | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6008321A (en) * | 1998-03-16 | 1999-12-28 | Pharmacopeia, Inc. | Universal linker for combinatorial synthesis |
US6281331B1 (en) | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
CA2323757C (fr) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Variants d'anticorps et fragments de ceux-ci |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
AU3871099A (en) | 1998-05-06 | 1999-11-23 | Temple University - Of The Commonwealth System Of Higher Education | Reversal of proinflammatory response by ligating the macrophage fcgammari receptor |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
AU4090299A (en) * | 1998-05-20 | 1999-12-06 | Sdg, Inc. | Liposomal delivery complex |
US6355782B1 (en) | 1998-07-09 | 2002-03-12 | Baylor College Of Medicine | Hypohidrotic ectodermal dyplasia genes and proteins |
US6596847B2 (en) | 1998-07-15 | 2003-07-22 | Genentech, Inc. | Tissue factor protein variants |
WO2000006605A2 (fr) * | 1998-07-28 | 2000-02-10 | Micromet Ag | Heterominicorps |
EP1105427A2 (fr) * | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Production de molecules modifiees avec demi-vie serique prolongee |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
DE69931382T2 (de) * | 1998-09-30 | 2007-05-03 | New England Biolabs, Inc., Ipswich | Intein vermittelte peptidligation |
EP1124961B9 (fr) | 1998-10-23 | 2010-07-21 | Kirin-Amgen Inc. | Composes thrombopoietiques |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP4463988B2 (ja) | 1998-11-06 | 2010-05-19 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子の生産方法 |
US6280994B1 (en) * | 1998-11-25 | 2001-08-28 | Zymogenetics, Inc. | Zace 1: a human metalloenzyme |
EP1006183A1 (fr) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Récepteurs Fc recombinantes et solubles |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
PT1141014E (pt) | 1999-01-06 | 2005-04-29 | Genentech Inc | Variante mutante do factor de crescimento semelhante a insulina (igf-i) |
PT1141015E (pt) | 1999-01-06 | 2009-10-13 | Genentech Inc | Variantes mutantes do factor de crescimento do tipo insulina (igf)i |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1141024B1 (fr) * | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRENANT UNE VARIANTE DE LA REGION Fc DE L'IgG1 HUMAIN |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
CA2270600A1 (fr) * | 1999-05-03 | 2000-11-03 | Infectio Recherche Inc. | Methode et preparations pour le traitement de maladies, en particulier de celles causees par le virus de l'immunodeficience humaine et leishmania |
CZ20014123A3 (cs) * | 1999-05-19 | 2002-06-12 | Lexigen Pharmaceuticals Corp. | Exprese a export interferonů-alfa jako Fc fúzních proteinů |
ES2307517T3 (es) * | 1999-07-01 | 2008-12-01 | Yale University | Inmunoconjugados dirigidos contra diana neovascular. |
AU6064400A (en) | 1999-07-02 | 2001-01-22 | Genentech Inc. | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
JP2003503426A (ja) * | 1999-07-02 | 2003-01-28 | ジェネンテック・インコーポレーテッド | FVIIaアンタゴニスト |
US6469136B1 (en) * | 1999-07-07 | 2002-10-22 | Trimeris, Inc. | Methods and composition for peptide synthesis |
AU782496B2 (en) * | 1999-07-13 | 2005-08-04 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
RU2263118C2 (ru) * | 1999-08-09 | 2005-10-27 | Лексиген Фармасьютикэлс Корп. | Комплексы антител с несколькими цитокинами |
CN1407900A (zh) * | 1999-10-14 | 2003-04-02 | 人类基因组科学公司 | 使用人骨髓祖细胞抑制因子-1(mpif-1)来治疗或预防细胞、组织、和器官损伤的方法 |
JP2003513660A (ja) | 1999-11-05 | 2003-04-15 | バイオジェン インコーポレイテッド | ヘッジホッグ融合タンパク質及び利用 |
JP2003514552A (ja) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
US6808902B1 (en) * | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
AU1920301A (en) * | 1999-11-17 | 2001-05-30 | Immunex Corporation | Receptor activator of nf-kappa b |
DE19963859A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
CA2397347C (fr) | 2000-02-11 | 2011-07-12 | Maxygen Aps | Molecules de type facteur vii ou viia |
JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
AU2001249389A1 (en) | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
AU5717301A (en) * | 2000-04-21 | 2001-11-07 | Amgen Inc | Apo-ai/aii peptide derivatives |
DE10020332A1 (de) | 2000-04-26 | 2001-11-15 | Henkel Kgaa | Wasch- und Reinigungsmittel |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
CA2410453A1 (fr) | 2000-05-26 | 2001-12-06 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides neuroprotecteurs |
US20040220388A1 (en) | 2000-06-30 | 2004-11-04 | Nico Mertens | Novel heterodimeric fusion proteins |
AU2001293231A1 (en) | 2000-09-01 | 2002-03-13 | Gryphon Therapeutics, Inc. | Nucleophile-stable thioester generating compounds, methods of production and use |
AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
US7138119B2 (en) | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
WO2002055110A2 (fr) | 2000-10-25 | 2002-07-18 | Genzyme Corp | Methods for treating blood coagulation disorders |
JP2004515233A (ja) * | 2000-11-01 | 2004-05-27 | イルーシス セラポーティクス,インコーポレーテッド | タンパク質トランススプライシングによる二重特異性分子の作製方法 |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
AU2002240120B2 (en) | 2001-01-29 | 2008-05-08 | Biogen Idec Inc. | Modified antibodies and methods of use |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
US20040132971A1 (en) * | 2001-02-09 | 2004-07-08 | Haaning Jesper Mortensen | Rank ligand-binding polypeptides |
EP1361891A2 (fr) * | 2001-02-19 | 2003-11-19 | MERCK PATENT GmbH | Proteines artificielles presentant une immunogenicite reduite |
US7235638B2 (en) | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
WO2002089828A2 (fr) | 2001-05-04 | 2002-11-14 | Institute Of Molecular And Cell Biology | Traitement de l'ischemie |
US7419949B2 (en) | 2001-07-16 | 2008-09-02 | Novo Noridsk Healthcare A/G | Single-dose administration of factor VIIa |
US7144380B2 (en) * | 2001-07-23 | 2006-12-05 | Gilliam Larry A | Traction method and device |
EP1288433B1 (fr) | 2001-08-31 | 2005-12-21 | Zeger De Lille | Appareil de forage |
EP1300419B1 (fr) | 2001-10-05 | 2007-06-13 | Affimed Therapeutics AG | Anticorps d'origine humaine pour l'inhibition de l'agrégation des thrombocytes |
FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
US20030078180A1 (en) * | 2001-10-24 | 2003-04-24 | Benchmark Research & Technology, Inc. | Contaminant-tolerant foaming additive |
US7737260B2 (en) | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Protein complex using an immunoglobulin fragment and method for the preparation thereof |
CA2841097A1 (fr) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumine et proteines hybrides g-csf |
US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20030180287A1 (en) * | 2002-02-27 | 2003-09-25 | Immunex Corporation | Polypeptide formulation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003209446B2 (en) | 2002-03-01 | 2008-09-25 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
JP2005526769A (ja) | 2002-03-15 | 2005-09-08 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 治療剤を全身搬送するための中央気道投与 |
PL374580A1 (en) | 2002-07-01 | 2005-10-31 | The Kenneth S.Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
JP2006513139A (ja) | 2002-07-03 | 2006-04-20 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 治療薬の全身性送達のための中央部気道投与 |
AU2003242507A1 (en) | 2002-07-12 | 2004-02-02 | Novo Nordisk A/S | A tissue factor binding immunoconjugate comprising factor viia |
US20040110929A1 (en) * | 2002-07-12 | 2004-06-10 | Bjorn Soren E. | TF binding compound |
JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス,インコーポレーテッド | FcγRIIB特異的抗体とその利用法 |
EP2364996B1 (fr) | 2002-09-27 | 2016-11-09 | Xencor Inc. | Variantes FC optimisées et leurs procédés de génération |
DE60334141D1 (de) | 2002-10-15 | 2010-10-21 | Facet Biotech Corp | VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
PT1624891E (pt) * | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
WO2004100882A2 (fr) | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Inhibition de medicament se liant a la serumalbumine |
US20050281829A1 (en) | 2003-05-06 | 2005-12-22 | Hehir Cristina A T | Fc chimeric proteins with anti-HIV drugs |
DE602004011770T2 (de) | 2003-06-12 | 2009-02-05 | Eli Lilly And Co., Indianapolis | Fusionsproteine |
US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
EP1697415A1 (fr) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees |
US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
JP2007511604A (ja) | 2003-11-18 | 2007-05-10 | アイコニック セラピューティクス インコーポレイティッド | キメラタンパク質の均質製剤 |
WO2005077981A2 (fr) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Polypeptides fc a nouveaux sites de liaison de ligands fc |
UA86605C2 (ru) | 2004-01-12 | 2009-05-12 | Аплайд Молекьюлер Иволюшн, Инк. | Антитело, которое содержит вариант исходного человеческого fс-участка |
US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
WO2005123780A2 (fr) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese |
DK1773872T3 (en) | 2004-05-21 | 2017-05-08 | Uab Res Found | VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof |
WO2006085967A2 (fr) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | Anticorps monoclonaux optimises anti-cd20 a variants fc |
CN103351434B (zh) | 2004-07-15 | 2015-09-30 | 赞科股份有限公司 | 优化的Fc变体 |
WO2006047350A2 (fr) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | Variants d'immunoglobuline igg a fonction effectrice optimisee |
US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
EP1868650B1 (fr) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Di-anticorps covalents et leurs utilisations |
US7427787B2 (en) | 2005-07-08 | 2008-09-23 | Texas Instruments Incorporated | Guardringed SCR ESD protection |
US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
EP1816201A1 (fr) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée |
EP1820508A1 (fr) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Polypeptides du facteur de coagulation X avec des propriétés d'activation modifiées |
CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
SI2004683T1 (sl) | 2006-03-24 | 2016-09-30 | Biogen Hemophilia Inc. | Pc5 kot encim za obdelavo propeptida faktorja ix |
DK2256135T3 (da) | 2006-06-14 | 2019-06-11 | Csl Behring Gmbh | Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
EP1952822A1 (fr) | 2007-01-26 | 2008-08-06 | Novo Nordisk A/S | Polypeptides de facteur VII avec une affinité améliorée pour les plaquettes |
EP2144930A1 (fr) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Fc à chaîne simple, procédés de fabrication et procédés de traitement |
MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
ES2400107T3 (es) | 2007-10-22 | 2013-04-05 | Merck Serono S.A. | IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado |
TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
WO2009140598A1 (fr) | 2008-05-16 | 2009-11-19 | Bayer Healthcare Llc | Facteurs de coagulation ciblés et procédés d'utilisation de ceux-ci |
WO2010115866A1 (fr) | 2009-04-06 | 2010-10-14 | Novo Nordisk A/S | Administration ciblée aux plaquettes de protéines de facteur viii |
CA2764758C (fr) | 2009-06-25 | 2019-02-12 | The University Of North Carolina At Chapel Hill | Molecules chimeriques du facteur vii |
JP2013503140A (ja) | 2009-08-27 | 2013-01-31 | ノヴォ ノルディスク アー/エス | 活性化血小板に対する組織因子の標的化 |
PT2506868T (pt) | 2009-12-06 | 2018-02-23 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos e hibridos de factor viii-fc, e métodos de utilização dos mesmos |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
MY192639A (en) | 2010-07-09 | 2022-08-29 | Bioverativ Therapeutics Inc | Factor ix polypeptides and methods of use thereof |
TW201217526A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
EP3508573A1 (fr) * | 2010-07-09 | 2019-07-10 | Bioverativ Therapeutics Inc. | Systèmes de traitement de facteur viii et procédés associés |
US20130337537A1 (en) | 2011-03-02 | 2013-12-19 | Novo Nordisk A/S | Coagulation factor-targeting to tlt-1 on activated platelets |
-
2004
- 2004-05-05 TW TW093112725A patent/TWI353991B/zh active
- 2004-05-06 CN CN2004800191889A patent/CN1852736B/zh active Active
- 2004-05-06 ES ES10182890.3T patent/ES2582947T3/es active Active
- 2004-05-06 EP EP10182902.6A patent/EP2357196B9/fr active Active
- 2004-05-06 EA EA200501756A patent/EA012566B1/ru not_active IP Right Cessation
- 2004-05-06 EP EP09013214.3A patent/EP2174946B1/fr active Active
- 2004-05-06 HU HUE10182890A patent/HUE030293T2/en unknown
- 2004-05-06 AT AT04751356T patent/ATE446307T1/de not_active IP Right Cessation
- 2004-05-06 HU HUE09013214A patent/HUE031663T2/en unknown
- 2004-05-06 EP EP04775946.9A patent/EP1625209B1/fr active Active
- 2004-05-06 BR BRPI0410345A patent/BRPI0410345A8/pt not_active Application Discontinuation
- 2004-05-06 UA UAA200511543A patent/UA95436C2/uk unknown
- 2004-05-06 PT PT101829026T patent/PT2357196T/pt unknown
- 2004-05-06 PL PL10182890.3T patent/PL2361932T3/pl unknown
- 2004-05-06 EP EP04751356A patent/EP1654378B1/fr active Active
- 2004-05-06 SI SI200432097T patent/SI1625209T1/sl unknown
- 2004-05-06 US US10/841,250 patent/US7404956B2/en active Active
- 2004-05-06 DK DK10182890.3T patent/DK2361932T3/en active
- 2004-05-06 CN CN201410443460.1A patent/CN104448003B/zh active Active
- 2004-05-06 DK DK09013214.3T patent/DK2174946T3/en active
- 2004-05-06 DK DK04775946.9T patent/DK1625209T3/da active
- 2004-05-06 EP EP10182890.3A patent/EP2361932B2/fr active Active
- 2004-05-06 EP EP16167345.4A patent/EP3103809B1/fr active Active
- 2004-05-06 HU HUE10182902A patent/HUE030065T2/en unknown
- 2004-05-06 US US10/842,054 patent/US7381408B2/en active Active
- 2004-05-06 PT PT101828903T patent/PT2361932T/pt unknown
- 2004-05-06 CA CA2522590A patent/CA2522590C/fr active Active
- 2004-05-06 EP EP21191566.5A patent/EP3978508A1/fr not_active Withdrawn
- 2004-05-06 WO PCT/US2004/013939 patent/WO2004101739A2/fr active Search and Examination
- 2004-05-06 WO PCT/US2004/014064 patent/WO2005001025A2/fr active Application Filing
- 2004-05-06 SI SI200432336A patent/SI2361932T1/sl unknown
- 2004-05-06 CN CN201110082150.8A patent/CN102234334B/zh active Active
- 2004-05-06 BR BR122019011535-4A patent/BR122019011535B1/pt active IP Right Grant
- 2004-05-06 JP JP2006532807A patent/JP5091480B2/ja active Active
- 2004-05-06 DK DK10182902.6T patent/DK2357196T3/en active
- 2004-05-06 SI SI200432335A patent/SI2357196T1/sl unknown
- 2004-05-06 ES ES04775946T patent/ES2431116T3/es active Active
- 2004-05-06 ES ES10182902.6T patent/ES2579938T3/es active Active
- 2004-05-06 DE DE602004023724T patent/DE602004023724D1/de active Active
- 2004-05-06 PL PL04775946T patent/PL1625209T3/pl unknown
- 2004-05-06 PL PL10182902.6T patent/PL2357196T3/pl unknown
- 2004-05-06 SI SI200432348A patent/SI2174946T1/sl unknown
- 2004-05-06 AU AU2004252422A patent/AU2004252422B2/en active Active
- 2004-05-06 PT PT47759469T patent/PT1625209E/pt unknown
-
2005
- 2005-11-03 IL IL171779A patent/IL171779A/en active Protection Beyond IP Right Term
- 2005-12-06 NO NO20055773A patent/NO339539B1/no active Protection Beyond IP Right Term
-
2006
- 2006-08-11 HK HK11113913.4A patent/HK1159649A1/zh unknown
- 2006-08-11 HK HK12101713.0A patent/HK1161604A1/zh unknown
- 2006-10-27 US US11/588,431 patent/US7862820B2/en active Active
-
2008
- 2008-04-09 US US12/100,183 patent/US7820162B2/en active Active
-
2010
- 2010-05-16 IL IL205802A patent/IL205802A/en active Protection Beyond IP Right Term
- 2010-10-22 US US12/910,265 patent/US20110159540A1/en not_active Abandoned
- 2010-11-23 US US12/952,551 patent/US8329182B2/en active Active
-
2012
- 2012-01-10 JP JP2012002429A patent/JP2012067142A/ja active Pending
- 2012-11-02 US US13/667,951 patent/US8932830B2/en active Active
-
2013
- 2013-10-16 CY CY20131100911T patent/CY1114639T1/el unknown
-
2014
- 2014-04-28 JP JP2014092357A patent/JP2014139244A/ja not_active Withdrawn
- 2014-10-31 US US14/530,256 patent/US9636416B2/en active Active
-
2015
- 2015-12-02 JP JP2015235339A patent/JP2016034977A/ja active Pending
-
2016
- 2016-03-08 HU HUS1600011C patent/HUS1600011I1/hu unknown
- 2016-03-09 LU LU92991C patent/LU92991I2/fr unknown
- 2016-03-09 NL NL300799C patent/NL300799I2/nl unknown
- 2016-03-15 FR FR16C0011C patent/FR16C0011I2/fr active Active
- 2016-03-17 LT LTPA2016007C patent/LTC1625209I2/lt unknown
- 2016-03-18 CY CY2016007C patent/CY2016007I2/el unknown
- 2016-03-22 NO NO20160483A patent/NO342384B1/no unknown
- 2016-04-06 BE BE2016C015C patent/BE2016C015I2/fr unknown
- 2016-07-11 CY CY20161100653T patent/CY1117764T1/el unknown
- 2016-07-11 CY CY20161100651T patent/CY1117756T1/el unknown
- 2016-10-18 LT LTPA2016028C patent/LTPA2016028I1/lt unknown
-
2017
- 2017-03-21 US US15/465,319 patent/US11401322B2/en active Active
- 2017-04-19 US US15/491,742 patent/US9725496B1/en active Active
- 2017-06-23 NO NO2017028C patent/NO2017028I2/no unknown
- 2017-06-23 NO NO2017027C patent/NO2017027I2/no unknown
- 2017-10-06 JP JP2017195992A patent/JP6441432B2/ja active Active
-
2018
- 2018-04-10 JP JP2018075260A patent/JP6526281B2/ja active Active
-
2019
- 2019-07-22 US US16/518,642 patent/US11168125B2/en active Active
-
2020
- 2020-06-12 NO NO2020016C patent/NO2020016I1/no unknown
-
2021
- 2021-09-21 US US17/480,984 patent/US20220010000A1/en not_active Abandoned
-
2022
- 2022-06-02 US US17/830,745 patent/US20230023927A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE2016C015I2 (fr) | ||
YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
PL1699822T3 (pl) | Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie | |
IL157446A0 (en) | Increased recovery of active proteins | |
IL172729A0 (en) | Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins | |
AU2013245463B2 (en) | Immunoglobulin Chimeric Monomer-Dimer Hybrids |